
    
      This is a single arm open-label study with a structured observation of INAD patients treated
      with RT001. Enrolled subjects will undergo observation and testing to determine the effect of
      RT001 treatment. Fifteen eligible subjects will be treated with RT001 for long-term
      evaluation of efficacy, safety, tolerability, and pharmacokinetics.
    
  